| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperkalemia | 14 | 2023 | 65 | 6.790 |
Why?
|
| Emergency Service, Hospital | 15 | 2025 | 1070 | 1.940 |
Why?
|
| Heart Failure | 9 | 2025 | 2127 | 1.370 |
Why?
|
| Emergency Medical Services | 7 | 2024 | 435 | 1.340 |
Why?
|
| Polymers | 3 | 2019 | 106 | 1.330 |
Why?
|
| Potassium | 7 | 2022 | 279 | 1.250 |
Why?
|
| Acute Coronary Syndrome | 4 | 2024 | 202 | 1.190 |
Why?
|
| Heart Arrest | 6 | 2024 | 340 | 1.080 |
Why?
|
| Pain | 3 | 2022 | 470 | 0.850 |
Why?
|
| Silicates | 3 | 2020 | 11 | 0.820 |
Why?
|
| Personal Protective Equipment | 2 | 2022 | 54 | 0.780 |
Why?
|
| Airway Management | 2 | 2022 | 66 | 0.780 |
Why?
|
| Pulmonary Edema | 1 | 2022 | 49 | 0.770 |
Why?
|
| Atrial Flutter | 1 | 2021 | 32 | 0.770 |
Why?
|
| Heart Injuries | 1 | 2021 | 46 | 0.760 |
Why?
|
| Cardiopulmonary Resuscitation | 5 | 2023 | 311 | 0.730 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 71 | 0.710 |
Why?
|
| Electrocardiography | 4 | 2023 | 958 | 0.690 |
Why?
|
| Infection Control | 1 | 2021 | 160 | 0.690 |
Why?
|
| Pneumonia, Bacterial | 1 | 2020 | 77 | 0.660 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2021 | 228 | 0.630 |
Why?
|
| Humans | 65 | 2025 | 123171 | 0.610 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 865 | 0.580 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2017 | 39 | 0.560 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2024 | 304 | 0.490 |
Why?
|
| Analgesics, Opioid | 4 | 2019 | 402 | 0.480 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 624 | 0.470 |
Why?
|
| Hypokalemia | 1 | 2014 | 41 | 0.450 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 477 | 0.440 |
Why?
|
| Pain Measurement | 5 | 2024 | 353 | 0.430 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2023 | 22 | 0.430 |
Why?
|
| Adult | 19 | 2025 | 29062 | 0.420 |
Why?
|
| Fever | 1 | 2015 | 296 | 0.420 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 161 | 0.410 |
Why?
|
| Ischemia | 1 | 2015 | 344 | 0.400 |
Why?
|
| Acute Disease | 4 | 2025 | 1094 | 0.390 |
Why?
|
| Patient Discharge | 4 | 2023 | 485 | 0.390 |
Why?
|
| Insulin | 4 | 2023 | 1200 | 0.390 |
Why?
|
| Biomarkers | 7 | 2025 | 2946 | 0.380 |
Why?
|
| Pain Management | 5 | 2024 | 175 | 0.370 |
Why?
|
| Albuterol | 2 | 2023 | 52 | 0.370 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2023 | 88 | 0.360 |
Why?
|
| Acetaminophen | 2 | 2024 | 91 | 0.360 |
Why?
|
| Predictive Value of Tests | 4 | 2025 | 2106 | 0.340 |
Why?
|
| Vitamin D | 2 | 2021 | 159 | 0.340 |
Why?
|
| Middle Aged | 16 | 2025 | 25994 | 0.330 |
Why?
|
| Ketamine | 2 | 2023 | 213 | 0.320 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2021 | 257 | 0.320 |
Why?
|
| Sufentanil | 2 | 2019 | 4 | 0.320 |
Why?
|
| Acute Pain | 2 | 2019 | 21 | 0.310 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 715 | 0.310 |
Why?
|
| Prospective Studies | 6 | 2024 | 6033 | 0.300 |
Why?
|
| Pilot Projects | 3 | 2022 | 1388 | 0.300 |
Why?
|
| Female | 21 | 2025 | 65500 | 0.280 |
Why?
|
| Male | 19 | 2025 | 60084 | 0.270 |
Why?
|
| Analgesia | 2 | 2024 | 44 | 0.250 |
Why?
|
| Aftercare | 2 | 2023 | 142 | 0.240 |
Why?
|
| Undocumented Immigrants | 1 | 2024 | 12 | 0.240 |
Why?
|
| Nasal Sprays | 1 | 2024 | 8 | 0.240 |
Why?
|
| Vitamins | 2 | 2021 | 107 | 0.230 |
Why?
|
| Hospitals | 3 | 2023 | 396 | 0.230 |
Why?
|
| Lipocalin-2 | 1 | 2024 | 28 | 0.230 |
Why?
|
| Renal Dialysis | 2 | 2022 | 842 | 0.230 |
Why?
|
| Ketorolac | 1 | 2024 | 17 | 0.230 |
Why?
|
| Microfluidics | 1 | 2024 | 18 | 0.230 |
Why?
|
| Dietary Supplements | 3 | 2022 | 472 | 0.220 |
Why?
|
| Myocardial Infarction | 2 | 2021 | 1000 | 0.220 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2023 | 4 | 0.220 |
Why?
|
| Hematology | 1 | 2024 | 38 | 0.220 |
Why?
|
| Ethics Committees, Research | 1 | 2023 | 33 | 0.210 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2024 | 107 | 0.210 |
Why?
|
| ROC Curve | 1 | 2025 | 556 | 0.210 |
Why?
|
| Cholesterol, HDL | 1 | 2024 | 348 | 0.210 |
Why?
|
| Trace Elements | 1 | 2022 | 24 | 0.210 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2025 | 274 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 263 | 0.200 |
Why?
|
| Peritoneum | 1 | 2002 | 36 | 0.200 |
Why?
|
| Monocytes | 1 | 2024 | 346 | 0.200 |
Why?
|
| Prognosis | 7 | 2024 | 4507 | 0.200 |
Why?
|
| Lymphocytes | 1 | 2024 | 401 | 0.200 |
Why?
|
| Long QT Syndrome | 1 | 2023 | 86 | 0.200 |
Why?
|
| Renin-Angiotensin System | 3 | 2020 | 95 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 6371 | 0.200 |
Why?
|
| Milrinone | 1 | 2022 | 30 | 0.200 |
Why?
|
| Aggression | 1 | 2024 | 226 | 0.200 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 2025 | 0.190 |
Why?
|
| Peptide Fragments | 2 | 2025 | 747 | 0.190 |
Why?
|
| Neutrophils | 1 | 2024 | 372 | 0.190 |
Why?
|
| Status Epilepticus | 1 | 2023 | 139 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 1068 | 0.190 |
Why?
|
| Mucormycosis | 1 | 2021 | 26 | 0.180 |
Why?
|
| Allied Health Personnel | 1 | 2022 | 74 | 0.180 |
Why?
|
| Dyspnea | 1 | 2022 | 147 | 0.180 |
Why?
|
| Myocarditis | 1 | 2021 | 119 | 0.180 |
Why?
|
| Airway Extubation | 1 | 2021 | 67 | 0.180 |
Why?
|
| Laryngoscopes | 1 | 2022 | 68 | 0.180 |
Why?
|
| Calcitonin | 1 | 2020 | 31 | 0.180 |
Why?
|
| Influenza, Human | 2 | 2024 | 649 | 0.170 |
Why?
|
| Medication Systems, Hospital | 1 | 2019 | 42 | 0.170 |
Why?
|
| Protein Precursors | 1 | 2020 | 149 | 0.170 |
Why?
|
| Hospitalization | 3 | 2023 | 1726 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2002 | 256 | 0.160 |
Why?
|
| Brain Ischemia | 1 | 2021 | 258 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2024 | 473 | 0.160 |
Why?
|
| Sodium Bicarbonate | 1 | 2019 | 52 | 0.160 |
Why?
|
| Cesarean Section | 1 | 2002 | 382 | 0.160 |
Why?
|
| Glucose | 1 | 2023 | 872 | 0.160 |
Why?
|
| Intubation, Intratracheal | 1 | 2022 | 291 | 0.150 |
Why?
|
| Codeine | 1 | 2018 | 24 | 0.150 |
Why?
|
| Diuretics | 1 | 2019 | 158 | 0.150 |
Why?
|
| Hydrocodone | 1 | 2018 | 35 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1009 | 0.150 |
Why?
|
| Pandemics | 5 | 2023 | 1101 | 0.150 |
Why?
|
| Influenza B virus | 1 | 2018 | 87 | 0.140 |
Why?
|
| Potassium, Dietary | 1 | 2017 | 12 | 0.140 |
Why?
|
| Calcium Gluconate | 1 | 2017 | 6 | 0.140 |
Why?
|
| Professional Practice Gaps | 1 | 2017 | 15 | 0.140 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2017 | 31 | 0.140 |
Why?
|
| Incidence | 3 | 2022 | 3047 | 0.140 |
Why?
|
| Influenza A virus | 1 | 2018 | 135 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 149 | 0.140 |
Why?
|
| Aged | 9 | 2025 | 19080 | 0.140 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2017 | 62 | 0.140 |
Why?
|
| Registries | 1 | 2023 | 1392 | 0.130 |
Why?
|
| Ketorolac Tromethamine | 1 | 2016 | 2 | 0.130 |
Why?
|
| Cardiology | 1 | 2021 | 472 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2020 | 478 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 673 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2021 | 376 | 0.130 |
Why?
|
| Administration, Intranasal | 1 | 2016 | 130 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 512 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 210 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 170 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 609 | 0.130 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2018 | 204 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 94 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2024 | 12129 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 714 | 0.120 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2015 | 27 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2016 | 158 | 0.120 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 100 | 0.120 |
Why?
|
| Leg | 1 | 2015 | 155 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2024 | 16021 | 0.110 |
Why?
|
| Potassium Chloride | 1 | 2014 | 54 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1096 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2017 | 366 | 0.110 |
Why?
|
| Stroke | 1 | 2021 | 958 | 0.110 |
Why?
|
| Medicare | 1 | 2017 | 424 | 0.110 |
Why?
|
| Leukocyte Count | 2 | 2024 | 247 | 0.110 |
Why?
|
| Radiography | 1 | 2015 | 823 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 607 | 0.100 |
Why?
|
| United States | 4 | 2024 | 10631 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 1151 | 0.100 |
Why?
|
| Thymidylate Synthase | 2 | 2004 | 22 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2020 | 1590 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2016 | 388 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2015 | 1168 | 0.090 |
Why?
|
| Prevalence | 1 | 2017 | 2406 | 0.090 |
Why?
|
| Age Factors | 1 | 2017 | 2802 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1088 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1262 | 0.090 |
Why?
|
| Administration, Sublingual | 2 | 2019 | 11 | 0.080 |
Why?
|
| Myocardium | 1 | 2014 | 984 | 0.080 |
Why?
|
| Risk Factors | 3 | 2022 | 10010 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3378 | 0.060 |
Why?
|
| Network Meta-Analysis | 1 | 2024 | 37 | 0.060 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 24 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2025 | 313 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2024 | 69 | 0.060 |
Why?
|
| Child | 3 | 2023 | 24237 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2024 | 3316 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 143 | 0.050 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2024 | 68 | 0.050 |
Why?
|
| Checklist | 1 | 2024 | 85 | 0.050 |
Why?
|
| Violence | 1 | 2024 | 112 | 0.050 |
Why?
|
| Propensity Score | 1 | 2024 | 207 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2023 | 101 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2024 | 218 | 0.050 |
Why?
|
| Glycopeptides | 1 | 2022 | 26 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 262 | 0.050 |
Why?
|
| Leukocytes | 1 | 2024 | 207 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2002 | 30 | 0.050 |
Why?
|
| Analgesia, Obstetrical | 1 | 2002 | 7 | 0.050 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2002 | 19 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 78 | 0.050 |
Why?
|
| Cystatin C | 1 | 2022 | 49 | 0.050 |
Why?
|
| Dobutamine | 1 | 2022 | 55 | 0.050 |
Why?
|
| Morphine | 1 | 2002 | 87 | 0.050 |
Why?
|
| Protective Factors | 1 | 2022 | 84 | 0.050 |
Why?
|
| Zinc | 1 | 2022 | 129 | 0.050 |
Why?
|
| Analgesics | 1 | 2022 | 135 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2002 | 158 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 380 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 135 | 0.050 |
Why?
|
| Health Promotion | 1 | 2024 | 390 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 445 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2023 | 371 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 418 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 420 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2020 | 84 | 0.040 |
Why?
|
| Resuscitation | 1 | 2022 | 244 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 951 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 293 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 826 | 0.040 |
Why?
|
| Automation, Laboratory | 1 | 2018 | 12 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1999 | 256 | 0.040 |
Why?
|
| Seizures | 1 | 2023 | 874 | 0.040 |
Why?
|
| Tablets | 1 | 2017 | 28 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2018 | 80 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2018 | 271 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 186 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 2025 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2024 | 821 | 0.030 |
Why?
|
| Length of Stay | 1 | 2002 | 1284 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2018 | 478 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 664 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 1337 | 0.030 |
Why?
|
| Animals | 2 | 2015 | 33749 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 751 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 622 | 0.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2018 | 334 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1683 | 0.030 |
Why?
|
| Enzyme Stability | 2 | 2004 | 58 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 849 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2004 | 316 | 0.020 |
Why?
|
| Ligands | 2 | 2004 | 533 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 3555 | 0.020 |
Why?
|
| Pregnancy | 1 | 2002 | 7148 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2838 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5773 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6217 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2004 | 103 | 0.010 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2004 | 23 | 0.010 |
Why?
|
| COS Cells | 1 | 2004 | 273 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 408 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2004 | 141 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2004 | 141 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 752 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2004 | 834 | 0.010 |
Why?
|
| Floxuridine | 1 | 1999 | 9 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2696 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3868 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 2771 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 661 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1061 | 0.010 |
Why?
|
| Protein Binding | 1 | 1999 | 1741 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 3091 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1999 | 2813 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2004 | 4489 | 0.010 |
Why?
|